Key Highlights

  • ImmuPharma PLC (LSE:IMM) is showing a 13.80% gain on 1 September 2026, making it one of the strongest percentage movers in the latest small-cap market snapshot.
  • The company has recently accelerated development of Kapiglucagon, a proprietary glucagon prodrug being developed for Type 1 diabetes applications.
  • In August, ImmuPharma selected Kymos Group as its bioanalytical partner for Kapiglucagon, supporting non-clinical and planned Phase 1 development work.
  • This followed the appointment of Thermo Fisher Scientific as drug-product development and Manufacturing partner in July and Bachem as active pharmaceutical ingredient manufacturing partner in June.
  • ImmuPharma completed a £6.47 million fundraising in April 2026, giving the company significantly more resources to advance Kapiglucagon while continuing development of its P140 platform.
  • P140 remains the company's lead asset and continues to be positioned around autoimmune diseases, including systemic lupus erythematosus.
  • Scientific research relating to P140 has also produced potential additional applications, including early-stage work investigating its potential relevance to glioblastoma, although the company's principal focus remains autoimmune disease.
  • ImmuPharma remains a development-stage biotech, so today's 13.80% gain is highly speculative and should not be interpreted as evidence of commercial profitability.
  • Investors are watching whether Kapiglucagon can move successfully from its current development programme into clinical testing and whether P140 can generate licensing or partnering opportunities.

Why ImmuPharma PLC (LSE:IMM) Is in Focus Today

ImmuPharma PLC (LSE:IMM) has attracted renewed investor attention after recording a 13.80% gain on 1 September 2026.

The move puts the specialist biotech company firmly among the day's notable small-cap healthcare stocks.

The most important point for investors is that the latest rally comes after a sequence of development milestones across ImmuPharma's drug pipeline.

Unlike a conventional pharmaceutical company with established commercial products and recurring sales, ImmuPharma's value is largely determined by the potential of its drug-development programmes.

That makes clinical progress, regulatory milestones, manufacturing readiness, intellectual-property developments, partnerships and funding particularly important.

The company currently has two especially important strategic pillars.

The first is P140, its lead autoimmune programme.

The second is Kapiglucagon, a newer proprietary glucagon prodrug programme aimed initially at Type 1 diabetes applications.

During 2026, management has been increasing the resources and infrastructure behind Kapiglucagon, creating a series of milestones that investors are now watching closely.

Kapiglucagon Is Becoming the Major Near-Term Growth Catalyst

Kapiglucagon is increasingly central to the ImmuPharma Investment story.

The drug is a proprietary glucagon prodrug designed to address some of the physicochemical limitations of native glucagon, particularly around solubility and formulation stability.

The company's initial focus is Type 1 diabetes, including potential use in dual-hormone artificial-pancreas systems and other glucagon-based therapeutic applications.

This is an important market opportunity.

Type 1 diabetes patients require insulin, and glucagon can play an important role in preventing or treating hypoglycaemia. Technologies that combine insulin and glucagon have therefore attracted significant research interest.

ImmuPharma is attempting to develop a version of glucagon that could be more suitable for advanced delivery systems.

The company is also evaluating a potential 505(b)(2) regulatory pathway in the United States, which could potentially Leverage existing information relating to native glucagon rather than requiring every aspect of the development programme to follow a completely new-drug pathway. The company has emphasised that the precise regulatory approach remains subject to confirmation.

For investors, the regulatory strategy matters because a more efficient pathway could potentially reduce development time and cost.

However, it does not eliminate clinical, regulatory or commercial risk.

Kymos Partnership Marks Another Development Milestone

The most recent major operational development came on 10 August 2026, when ImmuPharma selected Kymos Group as the bioanalytical contract research partner for Kapiglucagon.

Kymos is expected to support development and validation of regulated bioanalytical methods and analysis of samples generated during non-clinical and planned Phase 1 clinical programmes.

This is significant because it demonstrates that Kapiglucagon is moving beyond an early laboratory concept and into a more structured development programme.

A successful drug programme requires a network of specialist organisations covering manufacturing, analytical testing, formulation, toxicology, clinical development and regulatory preparation.

ImmuPharma is now assembling that infrastructure.

For investors, the next question is whether these development activities translate into a formal clinical programme and ultimately human safety and efficacy data.

That transition is often one of the most important value-creation stages for a biotech company.

Thermo Fisher Adds Manufacturing Credibility

The Kymos appointment followed ImmuPharma's selection of Thermo Fisher Scientific as its drug-product development and manufacturing partner in July 2026.

The appointment covers drug-product development and contract manufacturing activities for the Kapiglucagon programme.

This is another important step because manufacturing can become a major bottleneck for emerging biotech companies.

Producing a complex peptide-based medicine consistently and at the required quality is very different from demonstrating activity in laboratory experiments.

The appointment of an established specialist partner gives ImmuPharma access to manufacturing capabilities that would be difficult and expensive to build internally.

Investors should therefore view the Thermo Fisher relationship as part of the broader infrastructure being created around Kapiglucagon.

Bachem Strengthens the API Development Programme

In June, ImmuPharma appointed Bachem as the active pharmaceutical ingredient manufacturing partner for Kapiglucagon.

The company described the appointment as an important chemistry, manufacturing and controls milestone supporting the next stage of pharmaceutical development and preparation for regulatory submissions.

Taken together, the Bachem, Thermo Fisher and Kymos appointments show a clear progression.

Bachem — API manufacturing

Thermo Fisher — drug-product development and manufacturing

Kymos — bioanalytical support

This creates a more complete development infrastructure around Kapiglucagon.

That is one of the strongest reasons investors are watching ImmuPharma in September 2026.

The £6.47 Million Fundraise Changed the Financial Picture

Funding is another critical part of the story.

ImmuPharma completed a £6.47 million fundraising in April 2026, consisting of a £6 million subscription and a £470,000 retail offer.

This was strategically important because development-stage biotech companies typically require substantial funding before they can generate commercial revenue.

The additional Capital gives ImmuPharma greater financial flexibility to advance Kapiglucagon while continuing its P140 programme.

At the end of 2025, ImmuPharma had approximately £1.4 million of cash, compared with £0.2 million at the end of 2024. The company reported a 2025 loss of £1.8 million and Research and Development expenditure of £1.3 million.

The subsequent fundraising materially strengthened the company's resources.

However, investors should remember that development programmes consume cash rapidly.

The £6.47 million raised does not mean ImmuPharma is financially self-sustaining.

The key question is how efficiently the company converts that capital into development milestones and, ultimately, commercial or partnering value.

P140 Remains the Core Long-Term Asset

Although Kapiglucagon is generating much of the recent operational news, P140 remains extremely important to the ImmuPharma investment thesis.

P140 is the company's lead peptide platform for autoimmune disease and is associated with the programme known as Lupuzor.

The company's strategic focus remains on advancing P140 in autoimmune diseases, with licensing and partnering discussions also forming an important part of its commercial strategy.

This creates a potentially valuable dual-track investment story.

Kapiglucagon provides a relatively new development opportunity in metabolic disease.

P140 provides exposure to a longer-established autoimmune drug-development platform with years of research behind it.

If either programme generates a meaningful licensing or partnership transaction, the financial implications could be significant relative to ImmuPharma's current market capitalisation.

New Scientific Interest in P140 Adds Optionality

In June 2026, ImmuPharma highlighted research from the University of Murcia involving P140 and its potential application in glioblastoma.

The research was early-stage and did not change the company's primary strategy, which remains focused on autoimmune disease.

Nevertheless, the findings provide another indication that the underlying P140 mechanism could potentially have applications beyond its principal development programme.

For investors, this creates what can be described as pipeline optionality.

A successful drug platform can sometimes generate additional value when researchers discover potential applications in other diseases.

However, early-stage laboratory research should not be treated as evidence that P140 will become an effective treatment for glioblastoma.

The development path from laboratory research to a clinically validated medicine remains long and uncertain.

Why Today's 13.80% Move Matters

The 13.80% gain on 1 September 2026 is notable because ImmuPharma has been trading well below its 2025 highs.

Recent market data shows that the shares closed at approximately 3.50p on 28 August, after trading at substantially higher levels earlier in the year. The shares have also experienced considerable volatility, with the 52-week range extending from around 3.30p to 19p.

That Volatility is characteristic of a development-stage biotech company.

Share prices can react dramatically to relatively small changes in expectations surrounding clinical development, funding, partnerships and regulatory progress.

The latest gain should therefore be interpreted primarily as renewed investor interest and momentum around the pipeline, rather than as proof that the company has suddenly achieved commercial profitability.

There is no clear indication of a new same-day clinical result that independently explains the entire 13.80% rise.

Instead, the market appears to be reassessing the accumulation of recent Kapiglucagon milestones and the company's stronger funding position.

Why Investors Are Watching Kapiglucagon So Closely

The central question is whether Kapiglucagon can move from development infrastructure into actual clinical testing.

The company has now established important relationships covering manufacturing and bioanalytical work.

That means investors can begin focusing on the next sequence of milestones.

These include completion of non-clinical work, preparation for clinical studies, regulatory interactions, Phase 1 initiation and eventual human safety data.

Each milestone has the potential to influence the market's valuation of the programme.

Positive clinical data could materially increase the attractiveness of the asset to potential pharmaceutical partners.

Negative or delayed data could have the opposite effect.

This is why LSE:IMM remains a high-risk biotech investment.

The Type 1 Diabetes Market Provides a Large Opportunity

Kapiglucagon is being developed against a substantial global healthcare market.

Type 1 diabetes affects millions of people worldwide and requires lifelong management.

The growth of automated insulin-delivery systems and dual-hormone artificial-pancreas technologies creates potential Demand for improved glucagon formulations.

If Kapiglucagon can demonstrate advantages in formulation stability, solubility, delivery or other clinically relevant characteristics, it could potentially become attractive to companies developing advanced diabetes-management systems.

But market opportunity alone is not enough.

The product must demonstrate safety, efficacy, manufacturing consistency and commercial differentiation.

P140 Could Provide a Second Major Value Event

P140 provides another potential catalyst.

The programme has been the company's core scientific asset for many years, and management continues to explore licensing and partnering opportunities.

A licensing agreement could provide upfront payments, development funding, milestones and potentially royalties.

For a company with a Market Capitalisation of only around £22 million based on recent market data, even a relatively modest strategic transaction could potentially have a meaningful effect on valuation.

However, there is no guarantee that a deal will be completed.

Investors should therefore treat potential partnering activity as an opportunity rather than an assumed source of future cash.

The Biggest Risk Remains Clinical Development

The most important risk for ImmuPharma is clinical development failure.

Drug candidates can Fail because they are ineffective, unsafe, difficult to manufacture or commercially unattractive.

Even encouraging laboratory results do not guarantee successful human trials.

Kapiglucagon is still at an early development stage, while P140 faces its own development and partnering uncertainties.

The second major risk is funding.

Although the April fundraising significantly strengthened the balance sheet, continued development will consume cash.

If future programmes require more capital before meaningful commercial Revenue is generated, additional fundraising could become necessary.

Share Dilution Is Also Important

Investors should also monitor dilution.

The £6.47 million fundraising increased the company's financial resources but also increased the number of shares in issue.

Further capital raises could potentially dilute existing shareholders again.

For a small biotech company, this is particularly important because development programmes can take years and require multiple rounds of financing.

The best-case scenario is that ImmuPharma converts its stronger financial position into meaningful clinical and partnering milestones before another major funding requirement emerges.

What Investors Should Watch Next

The first major area to watch is Kapiglucagon's IND-enabling programme.

The market will want evidence that the non-clinical package is progressing towards clinical testing.

The second is the regulatory pathway.

Investors will want greater clarity around whether the proposed 505(b)(2) approach is accepted and how that affects the development timeline.

The third is manufacturing.

The Bachem and Thermo Fisher partnerships should support the transition towards clinical-grade material and drug-product preparation.

The fourth is bioanalytical development through Kymos.

The fifth is P140 partnering activity.

Any meaningful licensing or strategic partnership could become a major valuation catalyst.

The sixth is the company's cash position and development expenditure.

Overall Investor View

ImmuPharma PLC (LSE:IMM) has entered September 2026 with a significantly more developed Kapiglucagon infrastructure than it had at the beginning of the year.

The 13.80% share-price gain on 1 September 2026 therefore comes at an interesting point in the company's development.

The most important change is that Kapiglucagon is no longer simply a promising internal research project.

The company has now selected specialist partners covering API manufacturing, drug-product development and bioanalytical support.

That provides a clearer pathway towards non-clinical completion and eventual Phase 1 development.

At the same time, P140 remains the company's core autoimmune asset and could provide a separate source of value through further scientific development and potential licensing opportunities.

The April £6.47 million fundraising has also provided a substantially stronger financial foundation than the company had at the end of 2025.

But investors should remain realistic.

ImmuPharma has no established commercial revenue stream comparable with a mature pharmaceutical company.

The valuation remains heavily dependent on the success of future drug development.

Consequently, the latest 13.80% move should be viewed as a market response to improving development momentum rather than confirmation of a completed turnaround.

The key question now is whether ImmuPharma can convert its strengthened Balance Sheet and growing development infrastructure into clinical milestones, partnerships and eventually commercial value.

If Kapiglucagon progresses successfully towards human testing while P140 continues attracting strategic interest, LSE:IMM could remain an important speculative healthcare stock to watch.

If development is delayed, clinical results disappoint or additional funding becomes necessary before major commercial progress, the downside risk remains substantial.

For investors, the next phase is therefore about execution rather than simply excitement.